牛牛AI助理已提取核心訊息
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has successfully addressed a listing deficiency with The Nasdaq Stock Market. The company was previously notified by Nasdaq on September 1, 2023, that it did not meet the minimum Market Value of Publicly Held Shares (MVPHS) of $5,000,000 required for continued listing on the Nasdaq Global Market. However, ZyVersa Therapeutics received approval on February 29, 2024, to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effectively curing the MVPHS deficiency. The transfer became effective on March 1, 2024, with the company's common stock continuing to trade under the ticker symbol 'ZVSA'. The Nasdaq Capital Market has similar operational characteristics to the Nasdaq Global Market, but with different financial requirements. As of the transfer date, ZyVersa Therapeutics reported having 7,583,863 shares of common stock outstanding.
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has successfully addressed a listing deficiency with The Nasdaq Stock Market. The company was previously notified by Nasdaq on September 1, 2023, that it did not meet the minimum Market Value of Publicly Held Shares (MVPHS) of $5,000,000 required for continued listing on the Nasdaq Global Market. However, ZyVersa Therapeutics received approval on February 29, 2024, to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effectively curing the MVPHS deficiency. The transfer became effective on March 1, 2024, with the company's common stock continuing to trade under the ticker symbol 'ZVSA'. The Nasdaq Capital Market has similar operational characteristics to the Nasdaq Global Market, but with different financial requirements. As of the transfer date, ZyVersa Therapeutics reported having 7,583,863 shares of common stock outstanding.
生物製藥公司ZyVersa Therapeutics, Inc. 成功解決了納斯達克股票市場的上市缺陷。納斯達克此前曾於2023年9月1日通知該公司，該公司未達到繼續在納斯達克全球市場上市所需的公開持股股票（MVPHS）最低市值500萬美元。但是，ZyVersa Therapeutics於2024年2月29日獲得批准，將其普通股上市從納斯達克全球市場轉移到納斯達克資本市場，這有效地彌補了MVPHS的缺陷。此次轉讓於2024年3月1日生效，該公司的普通股繼續以股票代碼'ZVSA'進行交易。納斯達克資本市場的運營特徵與納斯達克全球市場相似，但財務要求不同。截至轉讓日，ZyVersa Therapeutics報告已發行7,583,863股普通股。
生物製藥公司ZyVersa Therapeutics, Inc. 成功解決了納斯達克股票市場的上市缺陷。納斯達克此前曾於2023年9月1日通知該公司，該公司未達到繼續在納斯達克全球市場上市所需的公開持股股票（MVPHS）最低市值500萬美元。但是，ZyVersa Therapeutics於2024年2月29日獲得批准，將其普通股上市從納斯達克全球市場轉移到納斯達克資本市場，這有效地彌補了MVPHS的缺陷。此次轉讓於2024年3月1日生效，該公司的普通股繼續以股票代碼'ZVSA'進行交易。納斯達克資本市場的運營特徵與納斯達克全球市場相似，但財務要求不同。截至轉讓日，ZyVersa Therapeutics報告已發行7,583,863股普通股。
有用
沒用